Did you know? You can suggest edits to improve this peptide information.
Overview
What is PNC-27?
PNC-27 is a 32-amino acid chimeric anticancer peptide developed in 2000 by Dr. Matthew Pincus and Dr. Joseph Michl at SUNY Downstate Medical Center using supercomputer modeling. It contains the HDM-2 binding domain of the p53 tumor suppressor protein (residues 12-26) linked to a membrane-penetrating peptide (MRP) derived from the Antennapedia penetratin sequence. PNC-27 selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes, forming transmembrane pores that cause rapid necrotic cell death — a process termed 'poptosis.' Normal cells, which lack membrane-associated HDM-2, are unaffected. A 2024 study revealed a secondary mechanism: PNC-27 also enters cells and selectively disrupts mitochondrial membranes while sparing lysosomes. Preclinical studies demonstrate efficacy against pancreatic, breast, melanoma, leukemia, ovarian, cervical, and other cancers. The FDA has issued explicit warnings against PNC-27 use due to contamination risks in marketed products and lack of approval. No verified human clinical trial data exists.
Key Benefits
Selective cancer cell killing via HDM-2 membrane targeting and mitochondrial disruption. Demonstrated efficacy against multiple cancer types in preclinical studies (pancreatic, breast, melanoma, leukemia, ovarian, cervical). Normal cells unaffected. Synergy with paclitaxel and ketone bodies documented.
Mechanism of Action
PNC-27 contains the p53 HDM-2-binding domain (residues 12-26) linked to a membrane-penetrating peptide. It binds HDM-2 overexpressed on cancer cell membranes, forming oligomeric transmembrane pore complexes that cause rapid necrotic cell death ('poptosis'). A secondary mechanism involves direct mitochondrial membrane disruption. Normal cells lack membrane HDM-2 and are unaffected, regardless of p53 mutation status.
Molecular Information
Weight
4031.72 Da
Length
32 amino acids
Type
Chimeric peptide (p53 domain + penetratin MRP)
Research Indications
Selective Cancer Cell Lysis
Kills cancer cells from multiple lineages (pancreatic, breast, melanoma, leukemia, ovarian, cervical) while sparing normal fibroblasts, lymphocytes, stem cells, and epithelial cells
p53-Independent Activity
Unlike intracellular HDM-2 inhibitors, PNC-27 targets membrane-associated HDM-2 and works regardless of p53 mutation status
Dual Mechanism of Action
Both plasma membrane pore formation and mitochondrial membrane disruption contribute to cancer cell death (2024 discovery)
Chemotherapy Synergy
Paclitaxel-surviving ovarian cancer cells upregulate membrane HDM-2, increasing susceptibility to PNC-27 — documented synergy via isobologram analysis
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
No established optimal timing. Community protocols suggest once daily at a consistent time. Short predicted half-life (minutes to hours) means daily dosing is required for sustained levels.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean work area and hands thoroughly
Calculate required BAC water volume using calculator below
Draw BAC water into syringe
Inject slowly down vial side (not directly onto powder)
Gently swirl until dissolved (never shake)
Store reconstituted vial in refrigerator at 2-8°C, use within 28 days
Quality Indicators
FDA Warning Issued
FDA has explicitly warned consumers to avoid PNC-27 products due to contamination and lack of approval
No Verified Human Trials
Claims of clinical trials exist in secondary sources but no NCT numbers or peer-reviewed results found
Third-Party Testing Required
Verify purity (>98% HPLC), sterility, and endotoxin levels through independent certificate of analysis (COA)
Lyophilized Powder Form
Should be supplied as white lyophilized powder — verify appearance matches expectations
Nebulized/Inhalable Products
FDA specifically cited contaminated inhalable PNC-27 products — avoid this route entirely
Cure Claims
Any vendor claiming PNC-27 is a proven cancer cure is making unsubstantiated claims — this is a research compound only
What to Expect
- NO established human efficacy data — all expectations are based on preclinical research
- Preclinical: Cancer cell death occurs within 90 minutes at effective concentrations in vitro
- Community protocols suggest 8-12 week cycles, but this is not clinically validated
- Injection site reactions are the most commonly reported side effect
- FDA has warned against use — consult an oncologist before considering
Side Effects & Safety
- NOT FDA approved — FDA has issued explicit warnings against PNC-27 use
- FDA found bacterial contamination (Variovorax paradoxus) in marketed PNC-27 products
- No verified human clinical trial data published in peer-reviewed journals
- No established human safety profile — preclinical data shows selectivity for cancer cells
- No published pharmacokinetic data in humans (half-life, bioavailability unknown)
- Should never replace FDA-approved cancer treatments
- Discuss with a qualified oncologist before any consideration of use
- Source quality is critical — third-party testing essential
- Avoid nebulized/inhalable forms (contamination risk cited by FDA)
References
Landmark PNAS Study — HDM-2 Binding Conformation (2010)
First major publication demonstrating PNC-27 adopts a p53-like structure when binding membrane HDM-2, forms transmembrane pores visualized by electron microscopy, and kills pancreatic, breast, and melanoma cancer cells while sparing normal fibroblasts.
View Study (opens in new tab) →Intact Peptide Mechanism Study (2010)
Demonstrated PNC-27 remains intact during membranolysis. Neither the p53 domain alone, the MRP alone, nor both domains uncoupled could induce cancer cell death — the chimeric linkage is essential for activity.
View Study (opens in new tab) →Leukemia Cell Selective Necrosis (2014)
Extended PNC-27's selectivity to non-solid tumors. Killed K562 leukemia cells at nearly 100% while showing no cytotoxicity to normal murine lymphocytes at any tested concentration. Confirmed necrotic (not apoptotic) cell death.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia